Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503921 | 0.92 | MAPK1 (0.53) | MAPK1PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL20504113 | 0.91 | MAPK1 (0.52) | MAPK1PIK3CDPIK3CBPIK3CAPTPN11 | |
| SCHEMBL20503948 | 0.91 | MAPK1 (0.55) | MAPK1PTPN11 | |
| SCHEMBL20503969 | 0.88 | MAPK1 (0.48) | MAPK1PIK3CAPTPN11MTOR | |
| SCHEMBL20504035 | 0.88 | MAPK1 (0.48) | MAPK1PTPN11 | |
| SCHEMBL20504012 | 0.88 | MAPK1 (0.48) | MAPK1PTPN11 | |
| SCHEMBL20503972 | 0.87 | MAPK1 (0.62) | MAPK1PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL25971022 | 0.87 | MAPK1 (0.72) | MAPK1PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL20503934 | 0.86 | MAPK1 (0.50) | MAPK1 | |
| SCHEMBL20504078 | 0.86 | MAPK1 (0.47) | MAPK1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-3377491-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885PIK3CD 387/4885PIK3CB 554/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885PIK3CD 224/4885PIK3CB 326/4885 |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885PIK3CD 224/4885PIK3CB 326/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885PIK3CD 387/4885PIK3CB 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.